Subsequently, Cobi+Reg was tested in the MM-386 model, an NRAS-mutant PDX line developed after progression on PD-1 blockade, and was superior to either agent alone, including evidence of tumor regression (Figure 3C), similar to that observed with the MM-337 model. Here, REG1A is linked to neoplasm.